Issue 5, 2014

Novel 3,5-bis(arylidiene)-4-piperidone based monocarbonyl analogs of curcumin: anticancer activity evaluation and mode of action study

Abstract

A series of eighteen novel 3,5-bis(arylidiene)-4-piperidone based symmetrical monocarbonyl analogs of curcumin were synthesised and a subset was screened by National Cancer Institute (NCI), USA for their anticancer activity. Dose–response studies and the mechanism of action investigation suggest that most active compounds are apoptosis inducers.

Graphical abstract: Novel 3,5-bis(arylidiene)-4-piperidone based monocarbonyl analogs of curcumin: anticancer activity evaluation and mode of action study

Supplementary files

Article information

Article type
Concise Article
Submitted
31 Dec 2013
Accepted
07 Feb 2014
First published
11 Feb 2014

Med. Chem. Commun., 2014,5, 576-586

Author version available

Novel 3,5-bis(arylidiene)-4-piperidone based monocarbonyl analogs of curcumin: anticancer activity evaluation and mode of action study

A. Thakur, S. Manohar, C. E. Vélez Gerena, B. Zayas, V. Kumar, S. V. Malhotra and D. S. Rawat, Med. Chem. Commun., 2014, 5, 576 DOI: 10.1039/C3MD00399J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements